Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is considered the most promising and effective th...

Full description

Bibliographic Details
Main Authors: Shinichi Makita, Katsuaki Imaizumi, Saiko Kurosawa, Kensei Tobinai
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2019-02-01
Series:Drugs in Context
Subjects:
axicabtagene ciloleucel
B-cell non-Hodgkin lymphoma
CAR-T
CD19
chimeric antigen receptor
diffuse large B-cell lymphoma
lisocabtagene maraleucel
tisagenlecleucel
Online Access:https://www.drugsincontext.com/chimeric-antigen-receptor-t-cell-therapy-for-b-cell-non-hodgkin-lymphoma:-opportunities-and-challenges

Internet

https://www.drugsincontext.com/chimeric-antigen-receptor-t-cell-therapy-for-b-cell-non-hodgkin-lymphoma:-opportunities-and-challenges

Similar Items